Malignant peritoneal mesothelioma
Jump to navigation
Jump to search
| Section editor | |
|---|---|
 |
Marjorie G. Zauderer, MD Memorial Sloan Kettering Cancer Center New York, NY |
1 regimens on this page
1 variants on this page
|
Guidelines
EURACAN/PSOGI
- 2020: Kusamura et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up
NCCN
Advanced or metastatic disease, subsequent lines of therapy
Atezolizumab & Bevacizumab
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Raghav et al. 2021 (MDACC 2016-0861) | 2017-2019 | Phase 2 |
Immunotherapy
- Atezolizumab (Tecentriq) 1200 mg IV once on day 1
Targeted therapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
References
- MDACC 2016-0861: Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. link to original article link to PMC article contains dosing details in manuscript PubMed Clinical Trial Registry